AKT1 and cancer: Therefore, since inhibition of PI3K-AKT and MEK-ERK signaling can diminish cell growth and promote cell death, targeting these signaling pathways by LY294002 and PD98059, inhibitors of PI3K-AKT and MEK-ERK signaling respectively, is being evaluated in clinical trials for cancer therapeutics.